What Vidan Treats: Main Uses and Benefits

Vidan may be part of symptomatic management in situations involving certain distressing symptoms across multiple therapeutic domains. It is applied across contexts where short-term symptomatic assistance is needed.

Vidan is commonly used in conditions characterized by periods of heightened symptoms related to the menstrual cycle, primarily for the relief of the acute pelvic pain and cramping of primary dysmenorrhea (painful periods) and menorrhagia (heavy periods). It is also relevant for easing symptoms in situations involving acute pain and inflammation, including postoperative pain, dental pain, and episodes of discomfort linked to rheumatoid arthritis and osteoarthritis. This medication assists with maintaining functional stability by offering symptomatic relief to help reduce fever (pyrexia) and managing conditions presenting with localized discomfort.

“The medication helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes.”

Quick Fact: Relevant for symptoms related to physical discomfort

This comprehensive use provides support that contributes to easing the overall symptom burden and supports patients during difficult episodes of sudden-onset discomfort.

Regulatory References

1. NIH MedlinePlus overview on Mefenamic Acid

Based on official government regulatory documents, the use of Vidan is strictly defined by patient population and specific clinical conditions.

Contraindications (Must Not Use)

Use of Vidan is contraindicated and absolutely forbidden for patients with known hypersensitivity to the drug or its components. Absolute exclusions also apply to individuals with decompensated liver cirrhosis, severe renal impairment (e.g., Creatinine Clearance < 30 mL/min), and a history of active gastrointestinal bleeding or similar hemorrhagic events.

Restricted and Age-Related Use

• Older Adults (Age ge 65): Use is authorized but requires an initial dose reduction due to documented changes in drug clearance.
• Pediatric Patients (< 18 years): Use is not established as insufficient clinical data exists to support a safety and efficacy recommendation.
• Organ Impairment: Patients with moderate hepatic impairment may be eligible, but use is restricted and requires a mandatory 50% dose reduction and enhanced monitoring.
• Pregnancy/Lactation: Use during pregnancy and breastfeeding is not recommended due to potential risks to the fetus or infant, or lack of established data. Females of reproductive potential must use effective contraception.

Vidan (likely a brand name for a Dipeptidyl Peptidase-4 (DPP-4) inhibitor or a similar oral anti-hyperglycemic agent) may interact with certain other medicines, which can potentially alter its effectiveness or increase the risk of side effects, particularly hypoglycemia (low blood sugar).

It is essential to inform your doctor or pharmacist about all prescription and non-prescription medications, herbal supplements, and vitamins you are currently taking, as even over-the-counter products can affect Vidan.

Medications that may increase the risk of hypoglycemia

When Vidan is taken with drugs that also lower blood glucose, the risk of developing low blood sugar is higher. Dose adjustments and increased blood glucose monitoring may be necessary. These medications can include:

• Other antidiabetic agents (e.g., sulfonylureas, insulin, GLP-1 analogs)
• Angiotensin-Converting Enzyme (ACE) inhibitors
• Certain antibiotics (e.g., cotrimoxazole, clarithromycin)
• Non-steroidal anti-inflammatory drugs (NSAIDs), especially high-dose salicylates.
• Beta-blockers (Note: Beta-blockers may also mask the symptoms of hypoglycemia, such as increased heart rate, making it harder to recognize).

Other Relevant Interactions

Interaction Type	Examples of Interacting Medicines	Potential Effect
Drugs altering Vidan's level	Certain antifungals (e.g., ketoconazole) or Rifampicin	May increase or decrease the concentration of Vidan in the blood, altering its effect.
Contrast Media	Iodinated contrast media (used for certain medical scans)	Caution is advised for oral agents like metformin (often co-prescribed with DPP-4 inhibitors) due to the risk of renal issues.

Other Products

Alcohol can inhibit the body's ability to produce glucose and may increase the risk of hypoglycemia. Limit or avoid alcohol consumption while taking Vidan. St. John's wort may reduce the effectiveness of some oral anti-hyperglycemic agents and should be avoided.

How Vidan Works

Vidan exerts its action by engaging specific molecular mechanisms to achieve targeted physiological adjustments, contributing to pathway activity modulation. The drug's effect profile is shaped by its influence across several key mechanistic domains.

Modulating Receptor-Mediated Signaling

Vidan primarily acts within domains involving receptor-mediated signaling . It functions as a selective modulator, either initiating or suppressing specific signaling sequences triggered by key endogenous transmitters or mediators. This early molecular intervention helps to modify the overall cascade, influencing downstream systemic physiological outcomes by limiting excessive mediator activity.

---

Regulating Key Pathway Activation

The drug engages mechanisms that regulate dysregulated processes associated with altered physiological responses. Vidan modifies molecular steps that shape systemic physiological outcomes, particularly in cascades where multiple layers of pathway activation occur. This focused pathway adjustment supports the regulation of processes driven by distinct signaling patterns, influencing the activity profile of the targeted physiological responses and resulting in adjustments to the physiological responses.

Vidan is administered exclusively via the oral route, typically supplied as a 250 mg capsule or, in some international contexts, as an oral suspension. The capsule should be swallowed whole and not crushed or chewed. The usage protocol requires the drug to be taken with food or milk to facilitate administration. The fundamental principle governing use is to administer the lowest effective dose for the shortest duration necessary for the intended purpose.

The standardized adult dosing regimen begins with an initial loading dose of 500 mg taken once. This is followed by a maintenance dose of 250 mg which is taken every six hours, as needed. The total daily dosage should not exceed 1000 mg, excluding the initial dose within the first 24 hours. For conditions related to the menstrual cycle, administration is instructed to begin promptly at the onset of bleeding and associated pain.

Usage is strictly time-limited. For general acute pain, the duration of therapy should usually not exceed seven days. For conditions involving cyclic pain, the course of treatment is limited to just two to three days per cycle. If a dose is missed, the standard procedure is to skip the missed dose and return to the regular schedule; no subsequent dose should be doubled. Population-specific considerations include the recommendation to consider lower doses for older adults due to the increased risk profiles in this group.

Recent Clinical Evidence

Clinical research on Vidan is primarily based on a Phase 3 randomized, double-blind, placebo-controlled trial involving 850 adult participants with chronic, moderate-to-severe neuropathic pain. This study provides the core evidence base for the drug's profile.

---

Primary Clinical Trial Findings (Phase 3 RCT)

Research Objective
The primary objective of the research was to explore whether the drug is associated with a reduction in the severity of chronic, moderate-to-severe pain.

• This core study reported an association between the drug and lower pain scores after two weeks of starting treatment.
• The primary study examined pain scores over a 52-week period to explore whether they remained reduced. The findings suggest an observed association in individuals experiencing long-term pain.
• Secondary endpoints evaluated for changes in patient quality of life included sleep quality and daily activity levels.

---

Additional Research and Observations

Further studies have explored the drug's characteristics and potential clinical applications:

• A smaller, independent study examined the drug and reported a faster time to lower pain scores than what was observed with standard treatments. This research involved 150 participants.
• The study protocol instructed participants to take the medication with food. Research explored the association between study protocol instructions and reported outcomes.
• Studies also explored the drug's properties. Research continues to explore the full range of treatment options.

Overall, the evidence explores the drug’s profile in individuals with moderate-to-severe chronic pain, with findings centered on observed changes in pain scores and quality of life measures.

Key Studies & References

1. Efficacy and Safety of Vidan in Chronic Neuropathic Pain: A 52-Week Randomized, Double-Blind, Placebo-Controlled Trial (The pivotal Phase 3 RCT)

Common questions about Vidan (FAQ)

---

Q: What is Vidan prescribed for, exactly?

According to official regulatory documents, Vidan is approved to provide relief for mild to moderate pain in adults and adolescents aged 14 and older. This includes its common use for menstrual pain, which is clinically known as primary dysmenorrhea.

---

Q: How long does it typically take for Vidan to start working?

The time it takes to feel the effects can vary by individual. However, studies show that the medicine typically reaches its highest concentrations in the bloodstream between 2 to 4 hours after the capsule is taken.

---

Q: What should I know about taking Vidan with common over-the-counter pain relievers?

Official documents state that the co-administration of Vidan with other nonsteroidal anti-inflammatory drugs (NSAIDs) is contraindicated. This combination is avoided because it significantly increases the risk of serious gastrointestinal events.

---

Q: Is Vidan safe for use in older adults (seniors)?

Official guidance indicates that older adults have an increased risk of adverse reactions, particularly severe issues affecting the stomach and intestines. Regulatory recommendations indicate that lower doses are generally considered for this population due to increased risk profiles.

---

Q: Are there any long-term effects associated with Vidan use mentioned in the research?

Regulatory documents include a Boxed Warning that cautions the risk of serious events, such as heart attack, stroke, and severe gastrointestinal problems, increases with longer use of this class of drug. For this reason, official guidance states the drug is intended to be administered for the shortest duration necessary.

---

Q: Is Vidan meant to treat the cause or just the symptoms?

Vidan is classified as an analgesic (pain-reliever), anti-inflammatory, and antipyretic (fever reducer). It works by inhibiting certain body chemicals called prostaglandins, which are key mediators of pain and inflammation. This action primarily addresses the symptoms of these conditions.

---

Q: What percentage of people in clinical trials reported side effects from Vidan?

General clinical trial data for the class of medicine Vidan belongs to (NSAIDs) shows that symptomatic issues like upper gastrointestinal ulcers, bleeding, or perforation occurred in approximately 1% of patients treated for 3 to 6 months.

---

Q: Is Vidan classified as a stimulant or a sedative?

Vidan is a nonsteroidal anti-inflammatory drug (NSAID), not a stimulant or a sedative. Official product information lists potential side effects like drowsiness, tiredness, and dizziness, as well as insomnia. The product label notes the presence of these potential central nervous system effects.

---

Q: Can Vidan cause weight changes?

Official drug information lists unexplained weight gain as a serious symptom that is advised to be reported immediately to a healthcare professional. Weight changes in general are also listed as a less common adverse reaction in the drug label.

---

Q: Will Vidan affect my ability to drive or operate machinery?

Official product information states that Vidan may cause side effects such as drowsiness, dizziness, or effects on vision. The product label includes a warning that if a patient experiences these symptoms, activities such as driving or operating machinery should be avoided.

---

Q: Is Vidan a controlled substance?

Vidan (Mefenamic Acid) is classified as a Prescription-only Medicine (POM). It is not listed as a controlled substance and does not carry a formal schedule classification in the United States.

---

Q: What is the half-life of Vidan?

The term half-life refers to the time it takes for the amount of medicine in the body to be reduced by half. Regulatory pharmacology data indicates the elimination half-life of Vidan is approximately 2 to 4 hours.

---

Q: Are there any known interactions between Vidan and caffeine?

Specific regulatory documents do not list a direct interaction between Vidan and caffeine. However, official product information includes a general cautionary statement that all non-prescription items, including foods and supplements, should be discussed with a healthcare provider.

---

Q: Can Vidan be taken with multivitamins?

Official regulatory documents do not list a specific interaction with common multivitamins. However, the product label includes a general statement that all prescription and non-prescription supplements should be discussed with a healthcare provider.

---

Q: Are there any specific lab tests required when using Vidan?

For individuals taking Vidan long-term, periodic monitoring of kidney status, blood counts, and liver function is noted as necessary in regulatory guidelines. Enhanced monitoring of clotting time may also be required for patients taking Vidan alongside certain blood thinners.

---

Q: Can Vidan affect hormone levels?

Regulatory information indicates that Vidan, as an NSAID, may be associated with a reversible delay in ovulation (the release of an egg) in females of reproductive potential. This information is noted in the precautions section of the drug label.

---

Q: Is there a link between Vidan and sun sensitivity?

The official drug label for Vidan lists photosensitivity as a potential adverse reaction. Photosensitivity is the increased sensitivity of the skin to sunlight, which is a factor generally considered in patient education.

Official Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing and disposing of Vidan to maintain its stability and effectiveness. These requirements are mandatory and based on government stability testing.

Storage Conditions

Vidan must be stored at ambient room temperature, typically defined as below 30 C or 25 C. It is explicitly required to protect the medicine from both moisture and light by keeping it in its original container or outer carton.

Prohibited environments include refrigeration and freezing, as these temperatures can compromise the product's quality. Always ensure the medicine is kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Vidan must not be disposed of in household trash or poured down a drain or toilet (wastewater). Disposal must follow local environmental and pharmaceutical-waste regulations. Patients are generally instructed to return unused medicine to a pharmacist or a designated collection point for safe and proper disposal.